Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
16 Maio 2023 - 9:30AM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
it has appointed David Mauro, M.D., Ph.D, as its Chief Medical
Officer. Dr. Mauro will lead Recursion’s pipeline into and through
clinical development, including its five programs currently in the
clinic, beginning June 1.
“We are incredibly excited to have Dr. Mauro join our team at
Recursion at such an important time in the development of our
clinical pipeline,” said Chris Gibson, Ph.D., Co-founder and CEO at
Recursion. “With his extensive background in oncology drug
development and a proven track record of advancing numerous
Investigational New Drug candidates, Dr. Mauro's expertise will be
a strong addition to our executive leadership team.”
Dr. Mauro has over 20 years in oncology drug development. His
notable accomplishments include guiding the translational,
preliminary, and later stages of development for more than 25
Investigational New Drug candidates over the past decade. His
previous roles include serving as the Chief Medical Officer for
Codiak BioSciences, Checkmate Pharmaceutical, Prelude Therapeutics,
and Advaxis. Dr. Mauro has also held leadership roles within the
clinical and medical affairs teams at Merck, Bristol Myers Squibb,
and Becton Dickinson.
Educated as a pharmacologist, Dr. Mauro received a B.S. in
Biochemistry from Cornell University and an M.D./Ph.D. from Temple
University. He completed his residency in anatomic pathology at the
National Institutes of Health's National Cancer Institute.
“I believe Recursion represents the future of drug discovery,”
said Dr. Mauro. “With five clinical programs and a growing number
of pre-clinical programs, I’m excited about the opportunity to
advance these into potential treatments for patients.”
About Recursion
Recursion is a clinical stage TechBio company leading the space
by decoding biology to industrialize drug discovery. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world’s largest
proprietary biological and chemical datasets. Recursion leverages
sophisticated machine-learning algorithms to distill from its
dataset a collection of trillions of searchable relationships
across biology and chemistry unconstrained by human bias. By
commanding massive experimental scale — up to millions of wet lab
experiments weekly — and massive computational scale — owning and
operating one of the most powerful supercomputers in the world,
Recursion is uniting technology, biology and chemistry to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding the timing for Dr. Mauro joining
Recursion; early and late stage discovery, preclinical, and
clinical programs; prospective products; Recursion OS and other
technologies; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as “plan,” “will,” “expect,” “anticipate,”
“intend,” “believe,” “potential,” “continue,” and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K. All
forward-looking statements are based on management’s current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024